THE MARK FOUNDATION FOR CANCER RESEARCH
Mark Foundation actively partners with scientists to accelerate research that will transform the prevention, diagnosis, treatment of cancer.
THE MARK FOUNDATION FOR CANCER RESEARCH
Status:
Active
Current Employees Featured
Raymond N. DuBois
Raymond N. DuBois Executive Chairman @ The Mark Foundation for Cancer Research Executive Chairman 2022-02-01
Ryan Schoenfeld
Ryan Schoenfeld CEO @ The Mark Foundation for Cancer Research CEO 2022-05-01
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-07-28 | Vicinitas Therapeutics | The Mark Foundation for Cancer Research investment in Series A - Vicinitas Therapeutics | 65 M USD |
2021-08-18 | Immunitas Therapeutics | The Mark Foundation for Cancer Research investment in Series B - Immunitas Therapeutics | 58 M USD |
2021-05-18 | Interius BioTherapeutics | The Mark Foundation for Cancer Research investment in Series A - Interius BioTherapeutics | 76 M USD |
2021-04-15 | C2i Genomics | The Mark Foundation for Cancer Research investment in Series B - C2i Genomics | 100 M USD |
2020-06-09 | C2i Genomics | The Mark Foundation for Cancer Research investment in Series A - C2i Genomics | 12 M USD |
2020-04-23 | Accent Therapeutics | The Mark Foundation for Cancer Research investment in Series B - Accent Therapeutics | 63 M USD |
2020-03-13 | Interius BioTherapeutics | The Mark Foundation for Cancer Research investment in Venture Round - Interius BioTherapeutics | 5.5 M USD |
2019-12-18 | The Jackson Laboratory | The Mark Foundation for Cancer Research investment in Grant - The Jackson Laboratory | 2.5 M USD |
2019-10-21 | Verseau Therapeutics | The Mark Foundation for Cancer Research investment in Venture Round - Verseau Therapeutics | 50 M USD |